Literature DB >> 11238701

Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study.

R M Hoffman1, F D Gilliland, J W Eley, L C Harlan, R A Stephenson, J L Stanford, P C Albertson, A S Hamilton, W C Hunt, A L Potosky.   

Abstract

BACKGROUND: African-Americans have twice the risk of non-Hispanic whites for presenting with advanced-stage prostate cancer. To investigate the reasons for this difference, we evaluated the association between race/ethnicity and advanced-stage prostate cancer, adjusting for demographic, socioeconomic, clinical, and pathologic factors.
METHODS: A population-based cohort of 3173 men diagnosed with prostate cancer between October 1, 1994, and October 31, 1995, was analyzed. Medical record abstracts and self-administered survey questionnaires were used to obtain information regarding race/ethnicity, age, marital status, insurance status, educational level, household income, employment status, comorbidity, urinary function, prostate-specific antigen level, tumor grade, and clinical stage. The odds ratio (OR) for advanced-stage prostate cancer was estimated with weighted logistic regression analysis. All P: values were two-sided.
RESULTS: Clinically advanced-stage prostate cancers were detected more frequently in African-Americans (12.3%) and Hispanics (10.5%) than in non-Hispanic whites (6.3%). Socioeconomic, clinical, and pathologic factors each accounted for about 15% of the increased relative risk. After adjusting for all covariates, the risk remained statistically significantly increased for African-Americans (OR = 2.26; 95% confidence interval [CI] = 1.43 to 3.58) but not for Hispanics (OR = 1.23; 95% CI = 0.73 to 2.08).
CONCLUSION: Traditional socioeconomic, clinical, and pathologic factors accounted for the increased relative risk for presenting with advanced-stage prostate cancer in Hispanic but not in African-American men.

Entities:  

Mesh:

Year:  2001        PMID: 11238701     DOI: 10.1093/jnci/93.5.388

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  145 in total

Review 1.  Prostate cancer detection strategies.

Authors:  Timothy C Brand; Javier Hernandez; Edith D Canby-Hagino; Joseph W Basler; Ian M Thompson
Journal:  Curr Urol Rep       Date:  2006-05       Impact factor: 3.092

2.  Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer.

Authors:  Vickie L Shavers; Martin L Brown; Arnold L Potosky; Carrie N Klabunde; W W Davis; Judd W Moul; Angela Fahey
Journal:  J Gen Intern Med       Date:  2004-02       Impact factor: 5.128

Review 3.  Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents.

Authors:  Norman H Lee
Journal:  Anticancer Agents Med Chem       Date:  2010-10-01       Impact factor: 2.505

4.  Racial disparities in stage-specific colorectal cancer mortality: 1960-2005.

Authors:  Samir Soneji; Shally Shalini Iyer; Katrina Armstrong; David A Asch
Journal:  Am J Public Health       Date:  2010-08-19       Impact factor: 9.308

5.  The Influence of Race on Overall Survival in Patients with Newly Diagnosed Bladder Cancer.

Authors:  Casey DeDeugd; Makito Miyake; Diego Aguilar Palacios; Charles J Rosser
Journal:  J Racial Ethn Health Disparities       Date:  2014-09-11

6.  African-American Men with Low-Risk Prostate Cancer: Modern Treatment and Outcome Trends.

Authors:  Augustine C Obirieze; Ambria Moten; Delenya Allen; Chiledum A Ahaghotu
Journal:  J Racial Ethn Health Disparities       Date:  2014-12-16

7.  TR4 nuclear receptor functions as a tumor suppressor for prostate tumorigenesis via modulation of DNA damage/repair system.

Authors:  Shin-Jen Lin; Soo Ok Lee; Yi-Fen Lee; Hiroshi Miyamoto; Dong-Rong Yang; Gonghui Li; Chawnshang Chang
Journal:  Carcinogenesis       Date:  2014-02-28       Impact factor: 4.944

8.  Leucine zipper, down regulated in cancer-1 gene expression in prostate cancer.

Authors:  Michele Salemi; Nunziata Barone; Sandro La Vignera; Rosita A Condorelli; Domenico Recupero; Antonio Galia; Filippo Fraggetta; Anna Maria Aiello; Pietro Pepe; Roberto Castiglione; Enzo Vicari; Aldo E Calogero
Journal:  Oncol Lett       Date:  2016-08-10       Impact factor: 2.967

9.  Veridical Causal Inference using Propensity Score Methods for Comparative Effectiveness Research with Medical Claims.

Authors:  Ryan D Ross; Xu Shi; Megan E V Caram; Pheobe A Tsao; Paul Lin; Amy Bohnert; Min Zhang; Bhramar Mukherjee
Journal:  Health Serv Outcomes Res Methodol       Date:  2020-10-20

10.  Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis.

Authors:  Che-kai Tsao; Alexander C Small; Max Kates; Erin L Moshier; Juan P Wisnivesky; Benjamin A Gartrell; Guru Sonpavde; James H Godbold; Michael A Palese; Simon J Hall; William K Oh; Matthew D Galsky
Journal:  World J Urol       Date:  2012-12-08       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.